Launch of Curaleaf International Driven by Liberalization of Cannabis Accelerating Across Europe

Spread the love

<![CDATA[

London, Nov. 1, 2021 – PRESS RELEASE – Curaleaf International (formerly EMMAC Life Sciences Group), part of Curaleaf Holdings, Europe’s largest vertically integrated cannabis company, is pleased to announce its official rebrand to the European market. It has been three years to the day since the U.K. government’s landmark decision to legalize cannabis-based products for medicinal use, paving the way for further significant developments to the cannabis sector. In this time, Curaleaf International has experienced exponential growth in cannabis revenues, as the demand for premium medicinal cannabis continues to grow.

Curaleaf International’s cannabis flower products and extracted cannabis-based products now supply five separate markets, including Germany, Europe’s largest market for medicinal cannabis, which is expected to be worth over €840 million by 2025. In the U.K., specifically over the last 12 months, the number of patients using the company’s products have increased fivefold. 

Building on the momentum within the European medicinal cannabis market, Curaleaf International expects to see significant regulatory change across Europe for adult-use cannabis over the coming years with expectations that the total European cannabis market will be worth €3.2 billion by 2025. Curaleaf International expects the trends to follow that of Canada and the U.S., which both started with the legalization of medicinal cannabis before moving to legalize cannabis for adult use. With a population of approximately 740 million people, Europe presents a greater market size than that of North America. 

The potential commercial impact of cannabis legalization in Europe is significant. One in 10 Europeans use cannabis every year, while a quarter of people admit to having used cannabis at least once in their lifetime. The annual sales in illicit market cannabis are estimated at around €11 billion.  As highlighted in The European Cannabis Report: 6th Edition, it is projected that sales of adult-use cannabis will reach €200 million by 2023, coming close to €800 million in 2025. Taking into account growth in the adult-use sector due to decreasing stigma and ease of access, Prohibition Partners increased its total market estimate from €800 million to €3.2 billion by 2025.

The Curaleaf International expects that over the next three to four years significant regulatory changes will occur across the continent. Recent progress has notably occurred in Switzerland, the Netherlands, Italy and Germany. Since May 2021, Switzerland allows the sale of adult-use cannabis under a trial basis. In Zurich, the country’s largest city, consumers will be allowed to buy cannabis products from pharmacies and social clubs. In the Netherlands, 10 licenses have been issued for an adult-use cannabis pilot project to supply 79 “coffee shops” in 10 municipalities. In Germany, the likely new coalition government under the SPD, Greens and FDP parties are all in favor of legalizing adult-use cannabis.

Additionally, Italy could be the first European nation to make adult-use cannabis legal. The country is due to have a referendum proposing the legalization of adult-use cannabis in 2022, with an expected result of 57% voting in favor of legalizing. The potential market presents a lucrative opportunity for first movers such as Curaleaf International. 

With the anticipated regulatory changes across Europe, Curaleaf International believes this is a pivotal moment for the European cannabis industry. The company is uniquely positioned within Europe with a fully vertically integrated model, handling every aspect of the process from seed to shelf. The company has two operating EU-good manufacturing practice (GMP) processing facilities and import and distribution capabilities in place in the U.K. and Germany.

Commenting on the European opportunity, Antonio Costanzo, CEO of Curaleaf International, said: “We have seen good growth in medicinal cannabis across Europe, and building on this momentum, the official launch of Curaleaf International has been designed to create a European cannabis platform to capitalize on the rapidly emerging opportunities that are accelerating in line with regulatory change and cultural acceptance. The landscape in Europe is changing and we can see similar clear patterns to the progress in North America for adult-use cannabis. As the only established fully integrated cannabis company in Europe, our first-mover advantage gives us complete control over the supply chain, and this, coupled with our science-led approach, leaves Curaleaf International best positioned to capitalize on this potentially enormous market.”

]]>
Source: One

Schaka

Related Posts

Dose-Related Inhibition of Capsaicin Responses by Cannabinoids CBG, CBD, THC and their Combination in Cultured Sensory Neurons

Aurora Cannabis Launches Genetics Licensing Business

Aurora Cannabis Launches Genetics Licensing Business

Steep Hill Announces Expansion to Illinois

Thompson Duke Industrial Secures Another Patent for Cannabis Oil Vaporizer Device Filling Equipment

Signez la pétition !!!

 

846 signatures

Pétition ASBL Cannabis Belgique

Pourquoi une pétition ?

Nous sommes des personnes qui en avons assez de devoir aller dans la rue et avoir affaire à des réseaux criminels sans savoir où cela va nous conduire par après.

Nous sommes des personnes ayant des maladies, qui pour certaines sont rares, et utilisant pour médication le cannabis sous diverses formes (CBD,THC,THCv,CBDa,,,) sous l'accord de notre médecin.

Nous sommes des personnes responsables et honnêtes qui avons une vie épanouie et sans problèmes de vie ou sociaux.

Nous avons également une passion pour la plante de cannabis en elle-même et la cultiver est notre bonheur. De plus, nous pouvons nous soigner avec notre médication sans avoir peur des produits ou autres additifs contenus dans une plante que l'on peut trouver autre part.

Nous souhaitons pouvoir avoir notre médicament dans les normes de la santé publique, car un cannabis sain aide à réduire les frais de santé parfois conséquents pour la collectivité et le malade lui-même.

Nous sommes également des personnes responsables avec un rôle dans la société qui en avons assez d’être considérés comme des « hippies ou autres drogués », nous avons juste choisi notre médication et celle-ci a apporté les preuves de son efficacité dans le monde.

Nous connaissons déjà les produits dérivés comme le CBD et le THC que nous maîtrisons pour nous aider dans notre maladie « Je précise que nous ne sommes pas médecin et que nous nous basons sur 20 ans d’expérience médicale du cannabis des membres de notre ASBL et l'avis du médecin de famille ».

Nous désirons simplement ne plus nous cacher, et pouvoir aider les autres personnes le souhaitant.

Nous somme soucieux des ados et de la prévention à leur égard. Effectivement, nous sommes les acteurs parfaits pour répondre aux questions qu’ils se posent vu notre expérience cannabique et, de plus, nous pourrons leur expliquer les risques qu’ils encourent en achetant du cannabis dans la rue.

Le projet complet peut être demandé via mail " info@mcb.care " et sur le site internet : " http://mcb.care "

@ASBL McB

**votre signature**

Partagez avec vos amis

Articles récents

Catégories